MCID: CNN010
MIFTS: 44

Connective Tissue Benign Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Benign Neoplasm

MalaCards integrated aliases for Connective Tissue Benign Neoplasm:

Name: Connective Tissue Benign Neoplasm 12 15
Soft Tissue Neoplasms 55 44 72
Soft Tissue Benign Neoplasm 12
Neoplasm of Soft Tissues 12
Tumor of the Soft Tissue 12
Neoplasm of Soft Tissue 12
Soft Tissue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060123
MeSH 44 D012983
NCIt 50 C3377
UMLS 72 C0037579

Summaries for Connective Tissue Benign Neoplasm

Disease Ontology : 12 A musculoskeletal system benign neoplasm that is located in connective tissue.

MalaCards based summary : Connective Tissue Benign Neoplasm, also known as soft tissue neoplasms, is related to desmoid tumor and bone benign neoplasm. An important gene associated with Connective Tissue Benign Neoplasm is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Pathways in cancer and MAPK Signaling: Mitogen Stimulation Pathway. The drugs Cranberry and Grape have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and lung, and related phenotypes are growth/size/body region and behavior/neurological

Related Diseases for Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 desmoid tumor 32.6 PDGFRB CTNNB1
2 bone benign neoplasm 31.5 USP6 HACD1 ERCC6 ENO2 CDC73
3 dermatofibrosarcoma protuberans 30.5 SERPINA3 PDGFRB CD34
4 malignant fibroxanthoma 30.5 SERPINA3 MDM2 CDK4
5 epithelioid leiomyosarcoma 30.4 SERPINA3 ENO2
6 leiomyosarcoma 30.2 PDGFRB MDM2 ENO2 CDK4
7 chondroid lipoma 30.2 MDM2 ENO2 CDK4
8 pseudosarcomatous fibromatosis 30.1 USP6 CTNNB1 CD34
9 liposarcoma 30.0 MDM2 CDK4 CD34
10 infiltrating lipoma 30.0 MDM2 CDK4 CD34
11 rhabdomyosarcoma 29.8 PTCH1 PDGFRB MDM2 ENO2 CDK4
12 plexiform schwannoma 29.8 ENO2 CD34
13 ewing sarcoma 28.9 PDGFRB MDM2 ENO2 CDK4 CD34
14 gastrointestinal stromal tumor 28.7 PDGFRB ENO2 CD34
15 sarcoma 11.8
16 fibroma 11.3
17 infantile myofibromatosis 11.3
18 spleen angiosarcoma 11.2
19 glomangiosarcoma 11.2
20 ring chromosome 7 10.7 MDM2 CDK4
21 infiltrating angiolipoma 10.6 MDM2 CDK4
22 spindle cell lipoma 10.6 MDM2 CDK4
23 cellular myxoid liposarcoma 10.6 MDM2 CDK4
24 undifferentiated embryonal sarcoma of the liver 10.5 SERPINA3 MDM2 CDK4
25 inflammatory mfh 10.5 SERPINA3 MDM2 CDK4
26 lipoblastoma 10.5 MDM2 CDK4
27 ossifying fibroma 10.5 MDM2 ERCC6 CDC73
28 hemangiopericytoma, malignant 10.4
29 bone osteosarcoma 10.4 MDM2 CDK4
30 malignant fibrous histiocytoma of bone 10.4 MDM2 CDK4
31 goblet cell carcinoid 10.4 ENO2 CTNNB1
32 periosteal chondrosarcoma 10.4 MDM2 CDK4
33 nodular medulloblastoma 10.3 PTCH1 CTNNB1
34 skin pilomatrix carcinoma 10.3 CTNNB1 CLEC2A
35 cellular neurofibroma 10.3 PDGFRB CD34
36 embryonal sarcoma 10.3 SERPINA3 MDM2 CTNNB1 CDK4
37 disseminated peritoneal leiomyomatosis 10.3
38 sclerosing liposarcoma 10.3 MDM2 CD34
39 heart sarcoma 10.3 PDGFRB MDM2 ENO2
40 calcifying epithelial odontogenic tumor 10.3 PTCH1 AMBN
41 kaposi sarcoma 10.3
42 spindle cell sarcoma 10.3
43 fibrosarcoma of bone 10.3 SERPINA3 PDGFRB MDM2 CDK4
44 rhabdomyosarcoma 2 10.3 MDM2 ENO2 CDK4
45 giant cell tumor 10.2
46 mixed liposarcoma 10.2 MDM2 CDK4 CD34
47 fibromatosis 10.2
48 periosteal osteogenic sarcoma 10.2 MDM2 CDK4 CD34
49 spindle cell liposarcoma 10.2 MDM2 CDK4 CD34
50 lung meningioma 10.2 ENO2 CD34

Graphical network of the top 20 diseases related to Connective Tissue Benign Neoplasm:



Diseases related to Connective Tissue Benign Neoplasm

Symptoms & Phenotypes for Connective Tissue Benign Neoplasm

MGI Mouse Phenotypes related to Connective Tissue Benign Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.15 AKTIP AMBN CDC73 CDK4 CTNNB1 ENO2
2 behavior/neurological MP:0005386 10.13 AKTIP CDC73 CDK4 CTNNB1 ENO2 ERCC6
3 integument MP:0010771 9.97 CD34 CDC73 CDK4 CTNNB1 ERCC6 HBEGF
4 craniofacial MP:0005382 9.95 AMBN CDC73 CTNNB1 ENO2 MDM2 PDGFRB
5 muscle MP:0005369 9.81 CDC73 CDK4 CTNNB1 ERCC6 HACD1 HBEGF
6 limbs/digits/tail MP:0005371 9.73 AKTIP CTNNB1 ERCC6 MDM2 PDGFRB PTCH1
7 neoplasm MP:0002006 9.56 AMBN CD34 CDC73 CDK4 CTNNB1 ERCC6
8 skeleton MP:0005390 9.28 AKTIP AMBN CDC73 CTNNB1 ERCC6 HBEGF

Drugs & Therapeutics for Connective Tissue Benign Neoplasm

Drugs for Connective Tissue Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Cranberry Approved, Investigational Phase 3
2 Grape Approved Phase 3
3
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
4
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
5
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Ifosfamide Approved Phase 3 3778-73-2 3690
10
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
11
Daunorubicin Approved Phase 3 20830-81-3 30323
12
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
13
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
14
Camptothecin Experimental Phase 3 7689-03-4
15
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
16 Cytochrome P-450 CYP3A Inducers Phase 3
17 Central Nervous System Stimulants Phase 3
18 Cytochrome P-450 Enzyme Inducers Phase 3
19 Wakefulness-Promoting Agents Phase 3
20 Vaccines Phase 3
21 Antirheumatic Agents Phase 3
22 Antibodies Phase 3
23 Immunoglobulins Phase 3
24 Antibodies, Monoclonal Phase 3
25 Alkylating Agents Phase 3
26
Liposomal doxorubicin Phase 3 31703
27 Anti-Bacterial Agents Phase 3
28 Antibiotics, Antitubercular Phase 3
29 Topoisomerase Inhibitors Phase 3
30 Antineoplastic Agents, Alkylating Phase 3
31 Antineoplastic Agents, Phytogenic Phase 3
32 topoisomerase I inhibitors Phase 3
33 Immunologic Factors Phase 3
34 Immunosuppressive Agents Phase 3
35 Tubulin Modulators Phase 3
36 Keratolytic Agents Phase 3
37 Dermatologic Agents Phase 3
38 Podophyllotoxin Phase 3 518-28-5
39 Etoposide phosphate Phase 3
40 Antimitotic Agents Phase 3
41
Isophosphamide mustard Phase 3 0
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
44
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
45
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
46
s 1 (combination) Phase 1, Phase 2
47 Carboxymethylcellulose Sodium Phase 1, Phase 2
48 Epinephryl borate Phase 1, Phase 2
49
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
2 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
3 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
4 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
5 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
6 The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors Completed NCT00001189 Phase 2
7 SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES Completed NCT02066675 Phase 2 Trabectedin
8 Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors Recruiting NCT02285439 Phase 1, Phase 2 MEK162
9 A Phase I Study to Determine the Dose of the Combination of Yondelis and Doxorubicin for Which Neutropenia is Manageable With the Support of Granulocyte-Colony Stimulation Factor in Subjects With Recurrent or Persistent Soft Tissue Sarcoma Completed NCT00102609 Phase 1 Doxorubicin;Trabectedin;Dexamethasone
10 Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Recruiting NCT02441972 Phase 1 18F-Al-NOTA-PRGD2 PET/CT
11 Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on. Recruiting NCT03159585 Phase 1 TAEST16001
12 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
13 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
14 Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NYESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 for Patients With Sarcoma Recruiting NCT03450122 Phase 1 Cyclophosphamide;Immunotherapeutic Combination Product CMB305
15 Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Recruiting NCT03093909 Phase 1 Gemcitabine
16 A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Terminated NCT02602067 Phase 1
17 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
18 Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002 Unknown status NCT00173355
19 Navigation Surgery for Bone and Soft Tissue Tumor Unknown status NCT01179698
20 Feasibility of the Third Space Robotic and Endoscopic Cooperative Surgery(TS-RECS) for Treating Gastric Stromal Tumor Completed NCT03804762
21 Radiofrequency Ablation of Painful Soft Tissue Neoplasms Completed NCT00041886
22 Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI Completed NCT01276483
23 Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors Completed NCT01630239 Early Phase 1
24 Quantitative MR Biomarkers for Sarcoma Treatment Completed NCT01017978
25 In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study Completed NCT01731379
26 Diagnostic Yield of Ultrasound-Guided Needle Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors Recruiting NCT03452644
27 An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry Recruiting NCT02677961
28 Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma Recruiting NCT02561559
29 Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study Recruiting NCT02557243
30 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Recruiting NCT03737734
31 The Use of Liposomal Bupivacaine (Exparel) in Soft Tissue Sarcoma Resection Recruiting NCT03867188 Early Phase 1 Liposomal Bupivacaine
32 Osteoarticular Tumor Characterization by Advanced Imaging Recruiting NCT02895633
33 A Pilot Study of Photoacoustic Imaging (PAI) Recruiting NCT03630601
34 Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors Recruiting NCT03751566 Standard supportive therapy
35 Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial Recruiting NCT02464696
36 Follow-up of Recurrences of Limb Soft Tissue Sarcomas in Patients With Localized Disease: Performance of Ultrasound Recruiting NCT02834585
37 Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites. Active, not recruiting NCT00582647
38 A Safety and Preliminary Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia Not yet recruiting NCT03886181
39 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Not yet recruiting NCT03889899
40 A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities Terminated NCT01965002 Aspirin;Enoxaparin
41 Prospective Multi-center National Swiss Sarcoma Cohort Study Terminated NCT02775799

Search NIH Clinical Center for Connective Tissue Benign Neoplasm

Inferred drug relations via UMLS 72 / NDF-RT 51 :


docetaxel

Cochrane evidence based reviews: soft tissue neoplasms

Genetic Tests for Connective Tissue Benign Neoplasm

Anatomical Context for Connective Tissue Benign Neoplasm

MalaCards organs/tissues related to Connective Tissue Benign Neoplasm:

41
Bone, Liver, Lung, T Cells, Skin, Prostate, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Benign Neoplasm:

19
Connective Tissue

Publications for Connective Tissue Benign Neoplasm

Articles related to Connective Tissue Benign Neoplasm:

(show top 50) (show all 470)
# Title Authors PMID Year
1
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 9 38
16707369 2006
2
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 9 38
16160477 2005
3
PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm. 38
31008539 2019
4
Prevalence of Neoplasms among Former Adolescent Psychiatric Inpatients. 38
31389225 2019
5
Diffusion-weighted imaging and diffusion tensor imaging as adjuncts to conventional MRI for the diagnosis and management of peripheral nerve sheath tumors: current perspectives and future directions. 38
30535638 2019
6
[Myxoid soft tissue tumours : An algorithm for differential diagnosis]. 38
31168638 2019
7
Skin and superficial soft tissue neoplasms with multinucleated giant cells: Clinical, histologic, phenotypic, and molecular differentiating features. 38
31306855 2019
8
GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. 38
31189998 2019
9
MRI imaging of soft tissue tumours of the foot and ankle. 38
31161474 2019
10
Spindle Cell Sarcoma of the Paraspinal Musculature with Late Pulmonary Metastases. 38
31186400 2019
11
[Clinicopathological characteristics and differential diagnosis of interdigitating dendritic cell sarcoma]. 38
31216832 2019
12
Large Undifferentiated Pleomorphic Sarcoma of the Posterior Thigh. 38
30853708 2019
13
Mesenchymal Tumors with EWSR1 Gene Rearrangements. 38
30709442 2019
14
Practical Application of Cytology and Core Biopsy in the Diagnosis of Mesenchymal Tumors. 38
30709446 2019
15
SWI/SNF Complex-Deficient Soft Tissue Neoplasms: A Pattern-Based Approach to Diagnosis and Differential Diagnosis. 38
30709441 2019
16
Targeted RNA sequencing: A routine ancillary technique in the diagnosis of bone and soft tissue neoplasms. 38
30350361 2019
17
Multinucleate cell angiohistiocytoma of the lower vermilion lip: an unusual site. 38
27706113 2019
18
Granular Cell Tumor over the Mons Pubis: An Uncommon Tumor. 38
31223510 2019
19
Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report. 38
30187166 2019
20
Limited biopsies of soft tissue tumors: the contemporary role of immunohistochemistry and molecular diagnostics. 38
30600320 2019
21
Imaging features of phosphaturic mesenchymal tumors. 38
29987349 2019
22
A novel case of an aggressive superficial spindle cell sarcoma in an adult resembling fibrosarcomatous dermatofibrosarcoma protuberans and harboring an EML4-NTRK3 fusion. 38
30175468 2018
23
Subcutaneous Phaeohyphomycosis: A Clinical Mimic of Skin and Soft Tissue Neoplasms-A Descriptive Study from India. 38
30105639 2018
24
Solitary fibrous tumor of the stomach with high-grade sarcomatous dedifferentiation. 38
30473761 2018
25
Paradoxical Examination and Imaging Findings in a Case of Paratesticular Cutaneous Angioyxoma. 38
29894778 2018
26
Applications of Ancillary Testing in the Cytologic Diagnosis of Soft Tissue Neoplasms. 38
30190145 2018
27
Pancreatic primitive neuroectodermal tumor: Focus on radiological features and differential diagnosis - A case report and literature review. 38
30249906 2018
28
Application of ancillary studies in soft tissue cytology using a pattern-based approach. 38
30156774 2018
29
Surgical management of truncal soft tissue sarcoma and other selected soft tissue neoplasms. 38
30173529 2018
30
Rapidly growing subcutaneous mass in an infant. 38
30142742 2018
31
Histology of ancient soft tissue tumors: A review. 38
29776878 2018
32
Cytologic diagnosis of round cell sarcomas in the era of ancillary testing: an updated review. 38
31043308 2018
33
Malignant granular cell tumors: the role of electron microscopy in the definitive diagnosis of an extremely aggressive soft tissue neoplasm. 38
29737916 2018
34
Large intramuscular lipoma of the tongue. 38
29904473 2018
35
An incidental finding of an asymptomatic intraneural glomus tumor: A case report and review of the literature. 38
29272030 2018
36
Nail Unit Glomus Tumor with Myxoid and Symplastic Change Presenting with Longitudinal Erythronychia. 38
29998102 2018
37
Treatment of primary tracheal glomus tumors: Two case reports and a literature review. 38
29642190 2018
38
Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition. 38
29439172 2018
39
Childhood cancer: incidence and spatial patterns in the city of Campinas, Brazil, 1996-2005. 38
30020360 2018
40
Magnetic resonance imaging appearance of foreign-body granulomatous reactions to dermal cosmetic fillers. 38
29279829 2017
41
MicroRNA expression in a phosphaturic mesenchymal tumour. 38
28932769 2017
42
Is Low FMR1 CGG Repeat Length in Males Correlated with Family History of BRCA-Associated Cancers? An Exploratory Analysis of Medical Records. 38
28667565 2017
43
Transungual resection of subungual glomus tumour. 38
28978594 2017
44
Philadelphia chromosome-positive acute myeloid leukemia with masses and osteolytic lesions: finding of 18F-FDG PET/CT. 38
28550639 2017
45
Paratesticular Soft-Tissue Masses in Orchiectomy Specimens: A 17-Year Survey of Primary and Incidental Cases From One Institution. 38
28459169 2017
46
The presence of neuroendocrine features generates a broad differential diagnosis in the fine-needle aspiration of bone and soft tissue neoplasms. 38
31043241 2017
47
Soft Tissue Neoplasms Causing Apparent Venous Thoracic Outlet Syndrome. 38
28259825 2017
48
A rare case of malignant solitary fibrous tumor in prostate with review of the literature. 38
28687087 2017
49
Malignant Rhabdoid Tumor of Soft Tissue. 38
28429647 2017
50
Giant lipoma of the hand causing median nerve compression. 38
28659368 2017

Variations for Connective Tissue Benign Neoplasm

Copy number variations for Connective Tissue Benign Neoplasm from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13803 1 1 56100000 Amplification Soft tissue tumor
2 21057 1 156500000 172900000 Amplification Soft tissue tumor
3 151970 20 27500000 41700000 Amplification Soft tissue tumor
4 178515 3 74200000 91000000 Amplification Soft tissue tumor
5 206336 6 139000000 161000000 Amplification Soft tissue tumor

Expression for Connective Tissue Benign Neoplasm

Search GEO for disease gene expression data for Connective Tissue Benign Neoplasm.

Pathways for Connective Tissue Benign Neoplasm

Pathways related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.44 PTCH1 PDGFRB MDM2 CTNNB1 CDK4
2
Show member pathways
11.85 PDGFRB MDM2 CDK4 AKTIP
3 11.77 PTCH1 MDM2 HBEGF CTNNB1
4 11.41 PDGFRB MDM2 CDK4 AKTIP
5 11.3 MDM2 HBEGF CDK4
6 10.97 PDGFRB MDM2 CTNNB1 CDK4

GO Terms for Connective Tissue Benign Neoplasm

Cellular components related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle membrane GO:0030666 9.13 PTCH1 MDM2 HBEGF
2 cell periphery GO:0071944 8.8 ODAM CTNNB1 CD34

Biological processes related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.71 PTCH1 MDM2 CTNNB1 CDK4
2 positive regulation of cell proliferation GO:0008284 9.65 PDGFRB MDM2 HBEGF CTNNB1 CDK4
3 response to estradiol GO:0032355 9.54 PTCH1 PDGFRB CTNNB1
4 cell fate determination GO:0001709 9.43 PTCH1 CTNNB1
5 odontogenesis of dentin-containing tooth GO:0042475 9.33 ODAM CTNNB1 AMBN
6 response to hyperoxia GO:0055093 9.32 PDGFRB CDK4
7 endodermal cell fate commitment GO:0001711 8.96 CTNNB1 CDC73
8 response to toxic substance GO:0009636 8.92 PDGFRB MDM2 ERCC6 CDK4

Molecular functions related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.5 USP6 SERPINA3 PTCH1 PDGFRB ODAM MRPL49

Sources for Connective Tissue Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....